BR112015023793A2 - composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a - Google Patents

composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a

Info

Publication number
BR112015023793A2
BR112015023793A2 BR112015023793A BR112015023793A BR112015023793A2 BR 112015023793 A2 BR112015023793 A2 BR 112015023793A2 BR 112015023793 A BR112015023793 A BR 112015023793A BR 112015023793 A BR112015023793 A BR 112015023793A BR 112015023793 A2 BR112015023793 A2 BR 112015023793A2
Authority
BR
Brazil
Prior art keywords
methods
replacement
individuals
factor vii
immune tolerance
Prior art date
Application number
BR112015023793A
Other languages
English (en)
Inventor
E Howard Tommy
La Terza Vicent
Original Assignee
Us Dept Veterans Affairs
Haplomics Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Dept Veterans Affairs, Haplomics Inc, Univ California filed Critical Us Dept Veterans Affairs
Publication of BR112015023793A2 publication Critical patent/BR112015023793A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a” é divulgado um peptídeo indutor de tolerância (tip) derivado do locus de referência do aminoácido (aarl) dentro de um produto de substituição do fviii (fviiirp) com base nas diferenças entre o produto da expressão do gene f8 de um sujeito (sfviii) e o fviiirp para proporcionar a indução de tolerância antes, durante, e/ou após uma terapia de substituição do fviii em um sujeito que sofre de hemophila a. métodos de obtenção, derivação e uso dos tip são também descritos. em algumas formas de realização, o tip é associado com uma nanopartícula, por exemplo, nanopartículas plga ou plga-pema.
BR112015023793A 2013-03-15 2014-03-17 composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a BR112015023793A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792102P 2013-03-15 2013-03-15
PCT/US2014/030314 WO2014145524A2 (en) 2013-03-15 2014-03-17 Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a

Publications (1)

Publication Number Publication Date
BR112015023793A2 true BR112015023793A2 (pt) 2017-07-18

Family

ID=51538489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023793A BR112015023793A2 (pt) 2013-03-15 2014-03-17 composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a

Country Status (4)

Country Link
US (1) US20160038575A1 (pt)
EP (1) EP2968499A4 (pt)
BR (1) BR112015023793A2 (pt)
WO (1) WO2014145524A2 (pt)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11235057B2 (en) 2011-04-29 2022-02-01 Selecta Biosciences, Inc. Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US11298342B2 (en) 2013-05-03 2022-04-12 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
US11633422B2 (en) 2014-09-07 2023-04-25 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
EP3691673A4 (en) * 2017-10-05 2021-06-09 Epivax, Inc. REGULATORY T-CELL EPITOPES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
EP2632479B1 (en) * 2010-10-27 2017-06-14 Baxalta GmbH Fviii peptides for immune tolerance induction and immunodiagnostics

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11235057B2 (en) 2011-04-29 2022-02-01 Selecta Biosciences, Inc. Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US11717569B2 (en) 2011-04-29 2023-08-08 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
US11779641B2 (en) 2011-04-29 2023-10-10 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
US11298342B2 (en) 2013-05-03 2022-04-12 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US11633422B2 (en) 2014-09-07 2023-04-25 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant

Also Published As

Publication number Publication date
EP2968499A4 (en) 2016-11-30
WO2014145524A3 (en) 2015-01-29
EP2968499A2 (en) 2016-01-20
WO2014145524A2 (en) 2014-09-18
US20160038575A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
BR112015023793A2 (pt) composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112015019064A2 (pt) métodos de tratamento de melanoma
BR112017019140A2 (pt) métodos de tratamento de câncer usando células t ativadas
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
BR112014017111A8 (pt) métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
PE20160878A1 (es) Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EA033444B1 (ru) Снижение вязкости фармацевтических составов
BR112014031841A2 (pt) formulação farmacêutica
EA201390617A1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
BR112017013696A2 (pt) peptídeos e seu uso no tratamento de pele
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]